We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cellartis Participates in Pioneering Stem Cell Collaboration in Scotland

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cellartis AB and its partners ITI Life Sciences and University of Glasgow have announced an extensive £9.5 million R&D programme to develop human stem cells for pharmaceutical research. The funding of the programme was made by ITI Life Sciences.

“This is an immensely exciting programme, and we are very much looking forward to participating in it. This important collaboration is in line with our strategic goal of scaling up our human embryonic stem cell technology”, commented Mats Lundwall, CEO of Cellartis.

“Life science research in Scotland, particularly in the stem cell area, is recognised internationally, and by establishing a research base in Scotland, we hope to contribute to the growth of this sector, while at the same time expanding our own business and operations in Scotland.”

According to Cellartis, the partnership is an acknowledgement of its technology and will contribute to sustaining the company’s global position in stem cell applications for drug discovery.

As part of this three-year programme, Cellartis is setting up an R&D and manufacturing facility at the Medipark in Dundee, creating a significant number of high-value jobs.

In addition to the ITI programme funding, Cellartis will receive a Regional Selective Assistance Award from the Scottish Executive for this establishment.